Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. by Krieger, Sophie, et al.
Inhibition of hepatitis C virus infection by anti-claudin-1
antibodies is mediated by neutralization of
E2-CD81-claudin-1 associations.
Sophie Krieger, Mirjam Zeisel, Christopher Davis, Christine Thumann, Helen
Harris, Eva Schnober, Christopher Mee, Eric Soulier, Cathy Royer, Me´lanie
Lambotin, et al.
To cite this version:
Sophie Krieger, Mirjam Zeisel, Christopher Davis, Christine Thumann, Helen Harris, et al..
Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutraliza-
tion of E2-CD81-claudin-1 associations.. Hepatology, Wiley-Blackwell, 2010, 51 (4), pp.1144-57.
<10.1002/hep.23445>. <inserm-00705657>
HAL Id: inserm-00705657
http://www.hal.inserm.fr/inserm-00705657
Submitted on 8 Jun 2012
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
For Peer Review
 1 
Inhibition of hepatitis C virus infection by anti-Claudin antibodies is 
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ABSTRACT 
The tight junction protein claudin-1 (CLDN1) has been shown to be essential 
for hepatitis C virus (HCV) entry – the first step of viral infection. Due to the 
lack of neutralizing anti-CLDN1 antibodies, the role of CLDN1 in the viral entry 
process is poorly understood. In this study, we produced antibodies directed 5 
against the human CLDN1 extracellular loops by genetic immunization and 
used these antibodies to investigate the mechanistic role of CLDN1 for HCV 
entry in an infectious HCV cell culture system and human hepatocytes. 
Antibodies specific for cell surface expressed CLDN1 specifically inhibit HCV 
infection in a dose-dependent manner. Antibodies specific for CLDN1, 10 
scavenger receptor B1 and CD81 show an additive neutralizing capacity 
compared to when either agent was used alone. Kinetic studies with anti-
CLDN1 and anti-CD81 antibodies demonstrate that HCV interaction(s) with both 
entry factors occur at a similar time in the internalization process. Anti-CLDN1 
antibodies inhibit the binding of envelope glycoprotein E2 to HCV permissive 15 
cell lines in the absence of detectable CLDN1-E2 interaction. Using fluorescent 
labelled entry factors and fluorescence resonance energy transfer (FRET) 
methodology, we demonstrate that anti-CLDN1 antibodies inhibit CD81-CLDN1 
association. In contrast, CLDN1-CLDN1 and CD81-CD81 associations were not 
modulated. Taken together, our results demonstrate that antibodies targeting 20 
CLDN1 neutralize HCV infectivity by reducing E2 association with the cell 
surface and disrupting CD81-CLDN1 interactions. In conclusion, these results 
further define the function of CLDN1 in the HCV entry process and highlight 
new antiviral strategies targeting E2-CD81-CLDN1 interactions. 
 25 
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INTRODUCTION 
With an estimated 170 million infected individuals, hepatitis C virus (HCV) has a 
major impact on public health. HCV is a hepatotropic virus that causes persistent 
infection in the majority of infected individuals (1). Therapeutic options for chronic 
infection are limited and a vaccine is not available (2). 5 
 
HCV entry into hepatocytes is the first step of the viral life cycle resulting in 
productive viral infection (3, 4). Furthermore, HCV entry is a major target of host 
neutralizing responses (5-7) and a target for antiviral immunopreventive and 
therapeutic strategies (for review see (4, 8)). Viral entry is believed to be mediated by 10 
the viral envelope glycoproteins E1 and E2 and several host entry factors. These 
include heparan sulfate, tetraspanin CD81, scavenger receptor class B type I (SR-BI) 
(3) and the tight junction (TJ) proteins claudin-1 (CLDN1) (9) and occludin (10, 11). 
As none of these host cell surface factors alone is able to promote HCV entry, the 
interaction of HCV and its target cells leading to the internalization of the virus is 15 
believed to be a multistep process involving the interplay of several host cell factors 
(3, 4, 8). 
 
Evans and colleagues reported that CLDN1 is essential for HCV infection (9). 
Subsequent studies demonstrated that CLDN-6 and -9 are also able to mediate HCV 20 
entry in non permissive cell lines (12, 13). CLDNs are critical components of TJs that 
regulate paracellular permeability and polarity and have a tetraspanin topology with 
four transmembrane domains, two extracellular and one intracellular loops, and N- 
and C-terminal cytoplasmic domains (14). CLDN1 extracellular loop 1 (EL1) is 
required for HCV entry (9) and is involved in barrier function and contributes to pore 25 
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formation between polarized cells (15). Mutagenesis studies in non-polarized 293T 
cells demonstrate that CLDN1 enrichment at cell-cell contacts may be important for 
HCV entry (16). We (17, 18) and others (16, 19, 20) using a variety of imaging and 
biochemical techniques reported that CLDN1 associates with CD81. However, due to 
the lack of neutralizing anti-CLDN1 antibodies targeting extracellular epitopes, the 5 
exact role of CLDN1 in the viral entry process is poorly understood. 
 
In this study, for the first time we produced anti-CLDN1 antibodies that bound 
to cell surface expressed CLDN1 and inhibited HCV infection. The anti-CLDN1 
antibodies inhibit HCV E2 glycoprotein interaction with permissive hepatoma cells 10 
and fluorescence resonance energy transfer (FRET) between CD81-CLDN1 co-
receptor complexes supporting a model where CLDN1 potentiates CD81 interaction 
with the virus and facilitates particle internalization. 
.
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MATERIALS AND METHODS 
Cells. Human Huh7 (5), Huh7.5.1 (21), HepG2 (18), 293T (5), Bosc (22), Caco-2 
(23), and rat BRL-3A hepatocyte-derived cell lines (24) were propagated in 
DMEM/10% foetal bovine serum. 293T/CLDN1 cells were obtained by stable 
transfection of 293T cells with a pcDNA3.1 vector encoding CLDN1 cDNA. DMSO-5 
mediated differentiation of Huh7.5.1 cells was performed as described (25). Primary 
human hepatocytes were isolated from liver resections from patients at the 
Strasbourg University Hospitals with approval from the Institutional Review Board 
(26, 27). In brief, liver specimen were perfused with calcium-free HEPES buffer 
supplemented with 0.5 mM EGTA (Fluka) followed by perfusion with HEPES buffer 10 
supplemented with 0.05% collagenase (Sigma) and 0.075% CaCl2 at 37°C. Following 
washing of cells with PBS and removal of nonviable cells by Percoll (Sigma) gradient 
centrifigation, freshly isolated hepatocytes (3 x 105 cells/well) were plated in 24-well-
plates pre-coated with collagen (Biocoat, BD Biosciences) and allowed to adhere in 
William’s E medium (Sigma Aldrich) containing 1 % Glutamax (Gibco), 1 % ITS 15 
(insulin transferrin selenium, Gibco), 10–7 M dexamethasone (Sigma), 0.15% bovine 
serum albumine (Sigma) and 10% fetal calf serum (PAN Biotec). 
 
Antibodies. Anti-CLDN1 antibodies were raised by genetic immunization of Wistar 
rats using a human CLDN1 cDNA expression vector. For screening, Bosc cells 20 
transfected with pCMV-SPORT6 or pCMV-SPORT6/CLDN1 were incubated with 
anti-CLDN1 or pre-immune serum and analyzed for cell surface CLDN1 expression 
by flow cytometry as described (28). Purified IgG from rat anti-CLDN1 serum were 
obtained by MAbTrapTM kit (GE Healthcare). To analyze cross-reactivity of antibodies 
with other members of the CLDN family, 293T cells were transfected to express 25 
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AcGFP tagged CLDN1, 4, 6, 7, 9, 11, 15 and 17 or chimeric CLDN1/7 (described in 
(9)) and 48 h later stained with rat anti-CLDN1 antibodies and Alexa-633 coupled 
anti-Rat Ig (Invitrogen). Cells were imaged by flow cytometry and data analyzed by 
FLowJo. Polyclonal rat anti-SR-BI or CD81 antibodies were obtained by genetic 
immunization as described (26). R-phycoerythrin-conjugated and Cy5-conjugated 5 
anti-rat IgG were from Jackson ImmunoResearch Laboratories, mouse IgG from 
Caltag, mouse anti-CD81 (JS-81) from BD Biosciences. 
 
Imaging studies of cell surface CLDN1. Living Huh7.5.1 cells were incubated with 
pre-immune or anti-CLDN1 serum (1/50) and a Cy5-conjugated anti-rat secondary 10 
antibody (1/300; Jackson ImmunoResearch). Polarized Caco-2 cells, as described in 
(23), were fixed in 3% paraformaldehyde, permeabilized with saponin and stained 
with polyclonal anti-CLDN1 (1/50) or control serum. Following staining, cells were 
fixed, mounted and observed using a Leica TCS SP2 CLSM (for Huh7.5.1) or a Zeiss 
Cell Axio Observer Z1 microscope (for Caco-2). 15 
 
Determination of tight junction barrier function. To determine the functionality of 
TJs and whether they restrict the paracellular diffusion of solutes from the bile-
canalicular (BC) lumen to the basolateral medium (barrier function), HepG2 cells 
were treated with either control (PBS), rat anti-CLDN1, rat control serum or IFNγ and 20 
incubated with 5 mM 5-chloromethylfluorescein diacetate (CMFDA; Invitrogen) at 
37°C for 10 minutes to allow internalization and translocation to BC lumen by MRP2. 
After washing with PBS, the capacity of BC lumens to retain CMFDA was analyzed 
as described (18). 
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HCVcc production and infection. HCVcc (Luc-Jc1 or Jc1 strains) were generated 
as described (6, 26, 29). For infection experiments, Huh7.5.1 cells were pre-
incubated in the presence or absence of antibodies for 1 h at 37°C and infected at 
37°C for 4 h with HCVcc. 48 h later HCV infection was analyzed in cell lysates by 
quantification of luciferase activity or viral RNA (6, 26, 29, 30). Kinetic studies in the 5 
presence of antibodies or inhibitors were performed as described (6, 26, 29, 30).  
 
HCV pseudoparticle (HCVpp) production and infection. Infection of 293T/CLDN1 
or Huh7.5.1 cells with MLV-based HCVpp in kinetic assays was performed as 
described (5, 6). Primary hepatocytes were infected with HIV-based HCVpp 10 
expressing envelope glycoproteins of strains HCV-J (genotype 1b), JFH-1 (genotype 
2a), UKN3A.1.28 (genotype 3a) and UKN4.21.16 (genotype 4) (described in (5)) 
containing a luciferase reporter element. One day following hepatocyte isolation and 
plating, hepatocytes were washed with PBS and pre-incubated with rat anti-CLDN1 
or control serum (1/50) for 1 hour at 37°C in William’s E medium. Then, HCVpp were 15 
added for 3 hours at 37°C. Following infection, the supernatant was removed and 
replaced by fresh William’s E medium. HCVpp infection was assessed by 
measurement of luciferase activity 72 hours post-infection as described (6, 26). 
 
Cellular binding of HCV envelope glycoproteins E1 and E2. Production and 20 
binding of C-terminally truncated envelope glycoproteins has been described (6, 24). 
For the study of E2-entry factor interaction, CHO cells were transfected with pcDNA3 
based expression vectors encoding SR-BI, CD81 or CLDN1 as described (31). 
Expression of entry factors was assessed by flow cytometry using anti-receptor 
antibodies as described (31). For the study of envelope glycoprotein binding in the 25 
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 9 
presence of anti-receptor antibodies, Huh7.5.1 cells (21) or rat BRL-3A cells stably 
expressing human SR-BI, CD81 and CLDN1 (24) were pre-incubated 1 h at RT with 
rat anti-SR-BI, -CLDN1, -CD81 serum (1/100) or mouse anti-human CD81 (JS-81; 5 
µg/mL) or control antibodies (1/100 or 5 µg/mL). Recombinant E2 (30 µL cell culture 
supernatant) or E1 (10 µg/mL) was added to cells for 1 h at RT. Following washing 5 
with PBS, bound envelope glycoproteins were detected using flow cytometry and 
human anti-E1 (IGH526 (6)) or mouse anti-His (RGS-His, Qiagen) and PE-
conjugated secondary antibodies (24, 28). For quantitation of HCVcc binding, 
Huh7.5.1 cells were pre-incubated with heparin (250µg/mL), rat anti-CLDN1 (1/50) or 
control serum (1/50) for 1 hour at 37°C prior to incubation with HCVcc (Jc1 strain) 10 
which had been partially purified from cell culture supernatants using sucrose 
gradient ultracentrifugation. Following incubation with HCVcc, non bound HCVcc 
were removed by washing of cells with PBS. Binding of HCVcc was then quantified 
by RT-PCR of cell bound HCV RNA as described (9). 
 15 
Receptor association using fluorescence resonance energy transfer (FRET). 
Homotypic and heterotypic interactions of CD81 and CLDN1 were analyzed as 
described (17, 18). Briefly, 293T cells transduced to express AcGFP and DsRED 
tagged CD81 and CLDN1 were grown on glass coverslips and fixed in ice-cold 
methanol. The cells were imaged on a Zeiss meta head LSCM, with microscope 20 
settings optimized for each fluorescent protein to obtain the highest signal-to-noise 
ratio. For FRET analysis, the gradual acceptor photobleaching method of FRET was 
used, which entailed photobleaching the DsRED fluorophore gradually over time 
while monitoring AcGFP fluorescent intensity (17). After background and cross-talk 
correction, any increase in AcGFP intensity following DsRED photobleaching is due 25 
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to FRET between proteins, implying a distance of less than 10 nm. The percent 
FRET is defined as the number of pixels that display FRET over the total number of 
pixels analyzed at the plasma membrane of the cells (17). The data from 10 cells 
were normalized and the localized expression calculated. 
 5 
Statistical analysis. Results are expressed the mean ± standard deviation (SD). 
Statistical analyses were performed using Student's t test with a P value of <0.05 
being considered statistically significant. 
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RESULTS 
Production of antibodies directed against cell surface CLDN1. To investigate the 
role of CLDN1 in HCV infection, we produced polyclonal anti-CLDN1 antibodies by 
genetic immunization and screened for reactivity with cell surface expressed CLDN1. 
Antibodies were selected for their ability to bind non-permeabilized Bosc cells 5 
transfected to express human CLDN1. Bosc cells are 293T-derived ecotropic 
packaging cells (22) which do not express endogenous CLDN1 (data not shown). As 
shown in Fig. 1A, incubation of Bosc cells expressing human CLDN1 with polyclonal 
anti-CLDN1 sera resulted in a specific interaction with CLDN1 extracellular domains 
(Fig. 1A). To confirm the specific interaction of anti-sera with CLDN1 we generated 10 
293T cells stably expressing human CLDN1 (Fig. 1B). Incubation of 293T/CLDN1 
cells with rat polyclonal anti-CLDN1 antibodies resulted in a specific interaction of 
these antibodies with human CLDN1 (Fig. 1B). These data demonstrate that anti-
CLDN1 antibodies obtained by genetic immunization specifically bind to the 
extracellular loops of human CLDN1 expressed on the cell surface. Using 293T cells 15 
transfected with tagged AcGFP tagged CLDN1, 4, 6, 7, 9, 11, 15 and 17 or chimeric 
CLDN1/7, we show that anti-CLDN1 antibodies demonstrate minimal or absent 
cross-reactivity against other members of the CLDN family (Table 1). 
  
Analysis of anti-CLDN1 reactivity to chimeric CLDN1/7 expressed on the cell 20 
surface of 293T cells demonstrated that the antibodies interact strongly with CLDN7 
where the N-terminal third (N1/3) or half (N1/2) was replaced with the corresponding 
coding region of CLDN1 (Table 1). In contrast, the antibodies did not exhibit any 
detectable interaction with CLDN7 where the C-terminal half (C1/2) of EL1 was 
replaced with the corresponding coding region of CLDN1. A reduced interaction was 25 
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observed for CLDN7 expressing the entire EL2 of CLDN1 (Table 1). These data 
demonstrate that anti-CLDN1 antibodies recognize epitopes in the N-terminal half of 
the CLDN1 EL1 which has been shown to be required for HCV entry (9) as well as 
EL2 epitopes (Table 1). Since antibodies failed to recognize overlapping peptides 
encoding for linear epitopes comprising the CLDN1 EL1 and 2 in an ELISA or an 5 
infection assay using peptides as capture antigens (data not shown), it is likely that 
epitopes targeted by anti-CLDN1 antibodies are conformation-dependent. 
 
To study whether anti-CLDN1 antibodies bind to CLDN1 on the cell surface of 
HCV permissive cells, Huh7.5.1 and primary human hepatocytes were incubated with 10 
anti-CLDN1 and analyzed by flow cytometry. Positive staining of human Huh7.5.1 
hepatoma cells and human hepatocytes with polyclonal anti-CLDN1 antibodies in the 
absence of permeabilizing reagents demonstrated that these antibodies bind to 
CLDN1 expressed on the surface of primary hepatocytes and HCV permissive cell 
lines (Fig. 1C). To further address the specificity of antibodies, we performed CLDN1 15 
knock-down experiments in Huh7.5.1 cells using a pool of three siRNAs described by 
Evans et al. (9). CLDN1 silencing resulted in a decrease of anti-CLDN1 staining in 
immunoblot analyses (data not shown) further confirming the specificity of the 
antibodies. 
 20 
Positive staining of native cell surface CLDN1 in living, non-permeabilized 
Huh7.5.1 cells with anti-CLDN1 antibodies was confirmed using imaging studies. 
Interestingly, in living native Huh7.5.1 cells, the antibody appeared to localize to 
certain areas of cell-cell contact (Fig. 1D), whereas in permeabilized Huh7.5.1 or 
Caco-2 cells antibody staining showed a polygonal web-like structure (Fig. 1D) which 25 
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was similar to previous studies using non-neutralizing anti-CLDN1 antibodies (23). 
CLDN1 staining appeared to be more pronounced in polarized Caco-2 cells than in 
non-polarized Huh7.5.1 cells (Fig. 1D). Further imaging studies are ongoing to 
determine the detailed subcellular localization of CLDN1 recognized by neutralizing 
anti-CLDN1 antibodies in HCV permissive cells.  5 
 
Taken together, these data demonstrate that anti-CLDN1 serum produced by 
genetic immunization specifically binds to the CLDN1 extracellular loops expressed 
on the cell surface of HCV permissive cell lines and human hepatocytes. 
 10 
Anti-CLDN1 antibodies do not affect tight-junction integrity. We previously 
reported that TJs impose a physical barrier and restrict viral access to receptors (23) 
and that complex hepatocyte-like polarity limits HCV entry (18). To investigate 
whether binding of anti-CLDN1 antibodies to polarized human hepatoma cells 
perturbed TJ integrity, we assessed the ability of TJs to restrict the paracellular 15 
diffusion of 5-chloromethylfluorescein diacetate (CMFDA) from the bile-canalicular 
(BC) lumen to the basolateral medium (barrier function) as previously described (18). 
As shown in Fig. 2, the capacity of BC lumens to retain CMFDA was similar in 
polarized HepG2 cells treated with rat anti-CLDN1 antibodies, rat control serum or 
PBS whereas CMFDA retention was reduced in IFNγ-treated HepG2 cells (Fig. 2B). 20 
These data suggest that anti-CLDN1 antibodies have no effect on TJ integrity.  
 
Neutralization of HCV infection by anti-CLDN1 antibodies. To investigate whether 
anti-CLDN1 antibodies could inhibit HCV infection, Huh7.5.1 cells were infected with 
chimeric J6/CF-JFH1 firefly luciferase reporter virus (Luc-Jc1) (26, 29) in the 25 
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presence of anti-CLDN1 or control antibodies. Fig. 3A shows that anti-CLDN1 serum 
inhibits Luc-Jc1 infection of Huh7.5.1 cells in a dose-dependent manner whereas the 
control pre-immune serum had no inhibitory effect. Neutralization of HCVcc infection 
correlated with binding of antibodies to the target cell line (Fig. 3B). To confirm that 
inhibition of Luc-Jc1 infection was mediated by anti-CLDN1 antibodies, we purified 5 
IgG from rat anti-CLDN1 and pre-immune serum. As shown in Fig. 3C, anti-CLDN1 
IgG but not control IgG markedly inhibited Luc-Jc1 HCVcc infection in a dose-
dependent manner. These data demonstrate that the inhibitory effect of anti-CLDN1 
serum was mediated by anti-CLDN1 IgG and not by other substances present in the 
serum. Infection experiments using primary human hepatocytes and HCVpp 10 
packaged with envelope glycoproteins from genotypes 1-4 demonstrated that anti-
CLDN1 blocking activity was similar for infection with HCV bearing envelope proteins 
of other genotypes (Fig. 3D). Taken together, these findings demonstrate that 
antibodies directed against the CLDN1 extracellular loops inhibit HCV infection in 
HCV permissive cell lines and human hepatocytes. 15 
 
CLDN1 acts cooperatively with CD81 and SR-BI in HCV entry. We previously 
demonstrated that CD81 and SR-BI act in concert to mediate HCV entry (26). To 
investigate whether the three host factors CLDN1, CD81 and SR-BI act in a 
cooperative manner, we added low concentrations of anti-receptor antibodies 20 
simultaneously prior to HCV infection. The use of antibody concentrations that sub-
maximally blocked HCV infection allowed us to observe additive or synergistic 
effects. First, we determined the ability of combinations of two out of the three 
antibodies to neutralize HCVcc infection. Fig. 4 shows an additive effect of the 
concomitant blocking of both CD81 and CLDN1 (Fig. 4B), SR-BI and CLDN1 (Fig. 25 
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4C) or CD81 and SR-BI (Fig. 4D). This effect was not observed when control IgG or 
control serum was used in combination with anti-CLDN1 antibodies (data not shown). 
Next, we assessed the impact of synchronously blocking all three host cell factors on 
HCVcc infection. Fig. 4E shows an additive effect of the three antibodies used. 
Indeed, Luc-Jc1 HCVcc infection was inhibited by more than 90% after simultaneous 5 
blocking of three host cell factors at antibody concentrations that inhibited HCVcc 
infection between 15% and 60% when used individually. Taken together, these 
results suggest that CLDN1 mediates HCV entry in cooperation with CD81 and SR-
BI. 
 10 
CLDN1 mediates an HCV entry step closely linked to HCV-CD81 interaction. To 
investigate the role of CLDN1 in the entry process, we investigated the inhibitory 
capacity of anti-CLDN1 antibodies in kinetic studies (26, 29). To discriminate 
between virus binding and post-binding events, Luc-Jc1 HCVcc binding to Huh7.5.1 
cells was performed for 1 h at 4°C in the presence or absence of inhibitors before the 15 
temperature was shifted to 37°C to initiate synchronous infection (Fig. 5A). Fig. 5B 
shows that similarly to anti-CD81 and anti-SR-BI, rat anti-CLDN1 inhibited Luc-Jc1 
HCVcc infection when added following binding of the virus to the target cell (Fig. 5B). 
To fine-map the entry step mediated by CLDN1, we added antibodies in side-by-side 
experiments every 20 min for up to 120 min after viral binding (Fig. 5C). The half-20 
maximal times (t1/2) required for anti-CD81 and anti-CLDN1 antibodies to inhibit HCV 
entry were +30 and +33 minutes (Fig. 5C-E; Table 2), whereas the half-maximal 
times for heparin was –60 minutes and for concanamycin A was +60 minutes (Fig. 
5C; Table 2). The time-course of anti-CLDN1 and anti-CD81-antibody-mediated 
inhibition was not significantly different, and both differed from those observed with 25 
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heparin and concanamycin A (Table 2). Similar results were obtained in DMSO 
differentiated Huh7.5.1 (27) cells (Fig. 5E). These data support a model where 
CLDN1 and CD81 exert their effects at a similar time in the viral internalization 
process. 
 5 
Using Flag-tagged CLDN1 transfected 293T cells, Evans et al. reported that 
anti-Flag inhibition of HCVpp infection occurred at later time points compared to a 
CD81 specific antibody (9). These results differ from those obtained in this study that 
may be attributable to the experimental systems used in the two studies, including: 
293T/CLDN1 versus Huh7.5.1 cell lines, HCVpp versus HCVcc, the strain of HCV 10 
envelope glycoproteins H77 versus J6/JFH1 and the blocking antibodies (anti-
CLDN1 versus anti-Flag). To further address this question, we studied the kinetics of 
anti-CLDN1 and anti-CD81 neutralization of HCVpp infection of 293T/CLDN1. 
Inhibition of HCVpp infection of 293T/CLDN1 cells by anti-CLDN1 and anti-CD81 
demonstrated a similar kinetics (Fig. 5F) to those observed for HCVcc infection of 15 
Huh7.5.1 cells (Fig. 5D, E). Thus, the different kinetic results described by Evans et 
al. and us are most likely not related to the experim ntal model system but rather 
related to the insertion of a Flag tag into CLDN1 (9). 
 
Anti-CLDN1 inhibits binding of envelope glycoprotein E2 to HCV 20 
permissive cells in the absence of CLDN1-E2 interactions. Next, we investigated 
whether anti-CLDN1 antibodies could interfere with E2 binding to permissive cell 
lines. Binding studies were performed using recombinant E1 and E2 glycoproteins in 
the presence of anti-receptor or control antibodies. As shown in Fig. 6B, anti-CD81, 
anti-SR-BI and anti-CLDN1 antibodies inhibited the binding of E2 to Huh7.5.1 cells. 25 
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In contrast, pre-immune or unrelated control serum had no effect (Fig. 6A-C). Similar 
results were obtained for antibody inhibition of E2 binding to BRL-3A rat hepatocyte-
derived cells engineered to express the three human entry co-factors, SR-BI, CD81 
and CLDN1 (24) (Fig. 6E). Expression of SR-BI, CD81 and CLDN1 on the cell 
surface of stably transfected BRL-3A cells was confirmed by flow cytometry and 5 
expression levels were comparable to Huh7 cells (data not shown and (24)). 
Interestingly, the magnitude of inhibition of E2 binding to Huh7.5.1 cells (Fig. 6C) 
correlated with the magnitude of inhibition of HCV infection (Fig. 3B), suggesting that 
inhibition of binding of E2-cell surface interactions provides a mechanism of action for 
the neutralizing activity of the anti-CLDN1 antibodies. In contrast, E1 binding was not 10 
affected by anti-CLDN1 (Fig. 6D). To investigate whether inhibition of E2 binding 
resulted in an inhibition of binding of infectious virions, we studied cellular binding of 
Jc1 HCVcc in the presence of anti-CLDN1 antibodies. Although HCVcc binding 
analyses were characterized by a higher inter-assay variability compared to E2 
binding studies, anti-CLDN1 antibodies markedly and significantly inhibited HCVcc 15 
binding to Huh7.5.1 cells (Fig. 6F). 
 
To study whether antibody inhibition of E2 binding to permissive cell lines was 
attributable to CLDN1 interactions with E2 we investigated whether CLDN1 was able 
to bind recombinant truncated glycoprotein E2. To address this question CHO cells 20 
were engineered to express human CLDN1, SR-BI or CD81 (Fig. 7A). Cell surface 
expression of human CD81 or human SR-BI conferred E2 binding to CHO cells (Fig. 
7B), whereas CLDN1 expression had no effect (Fig. 7B). These data suggest that 
CLDN1 does not interact directly with HCV envelope glycoprotein E2 and that 
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antibody blocking of E2-cell surface interactions may be mediated by indirect 
mechanisms. 
 
Anti-CLDN1 antibodies inhibit CLDN1-CD81 co-receptor association(s). Since 
anti-CLDN1 inhibits E2 binding to HCV permissive cells in the absence of a direct 5 
CLDN1-E2 interaction (Fig. 7B), we hypothesized that anti-CLDN1 antibodies may 
interfere with CD81-CLDN1 co-receptor complexes. To assess whether anti-CLDN1 
alter CLDN1-CD81 association, 293T cells were transfected to express AcGFP-CD81 
and DsRED-CD81 or AcGFP-CLDN1 and DsRED-CD81 or AcGFP-CLDN1 and 
DsRED-CLDN1 (17), incubated with pre-immune and anti-CLDN1 serum (1/100 and 10 
1/400) and co-receptor interaction(s) analyzed by FRET. As shown in Fig. 8, anti-
CLDN1 antibodies significantly reduced FRET between CD81 and CLDN1 in a dose-
dependent manner. Pre-incubation of cells with control serum did not modify CD81-
CLDN1 co-receptor interaction(s). Inhibition of CD81-CLDN1 co-receptor interaction 
was specific as shown by the unchanged FRET between CD81-CD81 and CLDN1-15 
CLDN1 following pre-incubation with anti-CLDN1 serum. Taken together, these data 
suggest that anti-CLDN1 antibodies interfere with CD81-CLDN1 heterodimer 
association. 
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DISCUSSION 
For the first time we report the genesis and characterization of antibodies directed 
against the extracellular loops of human CLDN1 which inhibit HCV infection. CLDN1 
showed no evidence for a direct association with the viral envelope E1E2 
glycoproteins and yet anti-CLDN1 serum inhibited E2 association with the cell 5 
surface and disrupted CD81-CLDN1 interactions. These data suggest a role for 
CD81-CLDN1 complexes in viral entry and highlight new antiviral strategies targeting 
co-receptor complex formation. 
 
CLDN1 is an essential co-factor conferring HCV entry (9), however, the 10 
precise role of CLDN1 in the multi-step entry process remains poorly understood. 
Using antibodies directed against CLDN1 EL, we demonstrate a dose-dependent 
inhibition of viral envelope association with HCV permissive cell lines. Using 
transfected CHO cells expressing human HCV entry factors, we demonstrate that in 
contrast to CD81 and SR-BI, CLDN1 does not directly interact with envelope 15 
glycoprotein E2 at the cell surface.  
 
Using a recent FRET-based system to study CD81-CLDN1 co-receptor 
association (17), we demonstrate that neutralizing anti-CLDN1 antibodies specifically 
disrupt CD81-CLDN1 FRET (Fig. 8). These data suggest that CD81-CLDN1 co-20 
receptor complexes are critical for HCV entry and CLDN1 may potentiate CD81 
association with HCV particles via E2 interactions. The functional relevance of the 
CD81-CLDN1 co-receptor complex for HCV entry is further corroborated by kinetic 
studies demonstrating that CD81 and CLDN1 act at a similar time point during HCV 
entry (Fig. 5). Although the magnitude of antibody-mediated inhibition of HCVcc 25 
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infection was slightly different, the kinetics of inhibition by anti-CLDN1 and anti-CD81 
were similar (Fig. 5C-F and Table 2).  
 
Using a HCVpp kinetic assay in 293T cells expressing Flag-tagged CLDN1 
and anti-Flag antibody, Evans et al. observed anti-Flag antibody inhibition of HCVpp 5 
infection at a later time point than anti-CD81, suggesting that CLDN1 has a role in 
late stages of the viral internalization process (9). Evans et al., reported that the 
inhibitory activity of anti-CD81 antibody was lost much earlier than the anti-Flag 
antibody (half-maximal inhibition at 18 and 73 min post temperature shift, 
respectively). However, we observed a loss of anti-CLDN1 and anti-CD81 inhibitory 10 
activity at similar times (half-maximal inhibition for both antibodies at +30 and +33 
min post temperature shift respectively). Comparable results using HCVpp infection 
of 293T/CLDN1 cells (Fig. 5F) suggest that the differences between the two studies 
relate to the inserted Flag epitope in CLDN1 sequence or the use of an anti-Flag 
antibody. It is conceivable that insertion of a triple Flag epitope into CLDN1 EL1 (9) 15 
may alter CLDN1 trafficking and possible association with CD81 resulting in a 
delayed inhibition of infection by anti-Flag antibody (9) compared to antibodies 
targeting native CLDN1. We conclude that CLDN1 and CD81 entry factors act in a 
cooperative manner in a closely linked step during HCV entry, consistent with earlier 
reports on CD81-CLDN1 association (17-19). 20 
 
Taken together, our findings support a model in which viral attachment and 
interaction with glycosaminoglycans and SR-BI promote or facilitate viral interaction 
with CD81-CLDN1 complexes. Since anti-CLDN1 inhibit envelope glycoprotein E2 
and virion binding to permissive cells in the absence of any detectable CLDN1-E2 25 
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interactions, it is conceivable that CLDN1 association with CD81 enhances viral 
glycoprotein association(s) to the HCV co-receptor complex that are required for 
virus internalization. These results define the function of CLDN1 in the HCV entry 
process and highlight new antiviral strategies targeting E2-CD81-CLDN1 interactions. 
 5 
The development of neutralizing anti-CLDN1 antibodies may provide new 
therapeutic options for the prevention of HCV infection. Our data clearly demonstrate 
that CLDN1 is a target for HCV therapeutic intervention that may complement 
ongoing efforts to block intracellular replication events with inhibitors of the HCV 
proteases and polymerase (9). The observation that anti-CLDN1 had no effect on 10 
HepG2 permeability and TJ integrity (Fig. 2) merits further investigation into the use 
of anti-CLDN1 antibodies as a therapeutic for HCV infection. The production of 
antibodies directed against HCV entry factors such as CLDN1 may widen the future 
preventive and therapeutic strategies for HCV infection and ultimately be used for the 
prevention of HCV infection following needle stick injury or during liver 15 
transplantation. Further efforts are underway to produce monoclonal anti-CLDN1 
antibodies for that strategy. 
 
In conclusion, our results suggest that viral entry requires the formation of a 
virus-co-receptor complex including HCV E2, CD81 and CLDN1. The functional 20 
mapping of E2-CD81-CLDN1 association and its impact for HCV entry has important 
implications for the understanding of the very first steps of HCV infection and the 
development of novel antiviral strategies targeting viral entry. 
 
 25 
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FIGURE LEGENDS 
Fig. 1. Production of antibodies directed against human CLDN1 extracellular 
domains using genetic immunization. (A) Specific binding of rat anti-human 
CLDN1 serum to CLDN1 expressed on the cell surface of transfected Bosc cells. 
Bosc cells were transfected with pCMV-SPORT6-CLDN1 (red histograms) or control 5 
vector (pCMV-SPORT6; black histograms). Flow cytometry of cells incubated with 
control serum (left panel) or anti-CLDN1 serum (right panel) demonstrated specific 
interaction of anti-CLDN1 antibodies with human CLDN1 (red histograms). The x and 
y axes show mean fluorescence intensities and relative numbers of stained cells, 
respectively. (B) Staining of cell surface CLDN1 on 293T/CLDN1 cells stably 10 
expressing CLDN1 by anti-CLDN1 antibodies. Flow cytometry of 293T/CLDN1 (clone 
IIIA6) cells (red histograms) or 293T parental cells (black histograms) incubated with 
control (left panel) or anti-CLDN1 IgG (right panel) demonstrated specific interaction 
of anti-CLDN1 antibodies with human CLDN1. (C) Cell surface expression of CLDN1 
on hepatoma cells lines or primary hepatocytes was determined by flow cytometry in 15 
the absence of permeabilization. Histograms corresponding to cell surface 
expression of CLDN1 (open curves) are overlaid with histograms of cells incubated 
with rat control serum (black shaded curves). (D) Imaging of cell surface CLDN1 on 
living Huh7.5.1 cells (left panels), permeabilized Huh7.5.1 (middle panels) and Caco-
2 (right panels) cells by anti-CLDN1 antibodies (upper panels). Cells incubated with 20 
control serum are depicted in the lower panels. Cells were incubated with pre-
immune serum or anti-CLDN1 and analyzed as described in Materials and Methods. 
Cell nuclei were stained with DAPI. 
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Fig. 2. Anti-CLDN1 antibody does not alter tight junction integrity in polarized 
HepG2 cells. (A) The bile canalicular (BC) lumen in polarized HepG2 cells was 
assessed for TJ “barrier” function. Cells were incubated with CMFDA, with restriction 
of the compound to the BC indicating that polarized HepG2 cells have functional TJs. 
(B) Polarized HepG2 cells grown for 3 days were treated with serum free DMEM for 5 
4h before being exposed to either control (PBS), irrelevant IgG control (1:100), anti-
CLDN1 Ab (1:100) or 10 ng/mL IFNγ for 1 h. TJ barrier function was measured by 
quantifying the number of BC retaining CMFDA compared to the total BC in a 
minimum of three fields of view on three replicate coverslips. *** P < 0.0001 (t test).  
 10 
Fig. 3. Dose-dependent inhibition of HCVcc infection by anti-CLDN1 antibodies. 
(A) Inhibition of Luc-Jc1 HCVcc infection by rat anti-CLDN1 serum. Huh7.5.1 cells 
were pre-incubated with serial dilutions of rat anti-CLDN1 serum or control rat serum 
for 1 h at 37°C before infection with Luc-Jc1 HCVcc for 4 h at 37°C. HCV infection 
was assessed by measurement of luciferase activity 48 h post-infection. Mean ± SD 15 
from a representative experiment performed in triplicate are shown. (B) Binding of 
anti-CLDN1 antibody to Huh7.5.1 cells. Huh7.5.1 cells were incubated with 
decreasing dilutions of anti-CLDN1 antibody and binding of anti-CLDN1 was 
determined by flow cytometry as described in Fig. 1. (C) Jc1 HCVcc infection in the 
presence of purified rat anti-CLDN1 IgG. Huh7.5.1 cells were pre-incubated for 1 h at 20 
37°C with serial dilutions of IgG isolated from rat anti-CLDN1 or control serum before 
infection with Jc1 HCVcc. 48 h later, HCV infection was analyzed by quantitation of 
HCV RNA using RT-PCR in intracellular lysates. Results are expressed as percent of 
HCVcc infectivity in the absence of antibody. Mean ± SD from a representative 
experiment performed in triplicate are shown. (D) Inhibition of HCVpp infection in 25 
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primary human hepatocytes by anti-CLDN1 antibodies. One day after isolation and 
plating, hepatocytes were washed and pre-incubated with rat anti-CLDN1 or control 
serum (1/50) for 1 hour at 37°C in medium. Then, HIV-based HCVpp bearing 
envelope glycoproteins of strains HCV-J (genotype 1b), JFH-1 (genotype 2a), 
UKN3A.1.28 (genotype 3a) and UKN4.21.16 (genotype 4) were added for 3 hours at 5 
37°C. Following infection, the supernatant was removed and replaced by fresh 
medium. HCVpp infection was assessed by measurement of luciferase activity 72 
hours post-infection. Inhibition of HCVpp infection is shown as % infection compared 
to hepatocytes incubated with control serum (=100%). *** P < 0.0001. 
 10 
Fig. 4. CLDN1, CD81 and SR-BI act in concert to mediate HCVcc entry. (A) Dose-
dependent inhibition of Luc-Jc1 HCVcc infection by anti-CLDN1, anti-CD81, and anti-
SR-BI antibodies. Huh7.5.1 cells were pre-incubated for 1 h at 37°C with control 
mouse IgG (0.1 µg/mL), control rat pre-immune serum (PI) (1/200), anti-CD81 
antibody JS-81 (0.1 and 0.05 µg/mL), rat anti-CLDN1 serum (1/100, 1/200, 1/400) or 15 
rat anti-SR-BI serum (1/200, 1/400, and 1/800) before infection with Luc-Jc1 HCVcc 
for 4 h at 37°C. HCV infection was assessed by measurement of luciferase activity 
48 h post-infection. Data are expressed as percent of Luc-Jc1 HCVcc infectivity in 
the absence of antibody. (B-E) Additive effects of anti-CD81 and anti-CLDN1 (panel 
B), anti-SR-BI and anti-CLDN1 (panel C), anti-CD81 and anti-SR-BI (panel D) and 20 
anti-CD81, anti-CLDN1 and anti-SR-BI antibodies (panel E) resulting in inhibition of 
HCVcc entry. Huh7.5.1 cells were pre-incubated for 1 h at 37°C with rat anti-CLDN1 
(1/200 and 1/400) mouse anti-CD81 JS-81 (0.1 µg/mL and 0.05 µg/mL) and rat anti-
SR-BI (1/400 and 1/800) antibodies either alone (black bars) or in combination before 
infection (grey bars) with Luc-Jc1 HCVcc for 4 h at 37°C. HCV infection was 25 
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assessed as described in (A). Data are expressed as percent of Luc-Jc1 HCVcc 
infectivity in the absence of antibody. Means ± SD of four independent experiments 
performed in duplicate are shown. *** P < 0.0001, ** P < 0.001 *, P < 0.01 (t test). 
 
Fig. 5. Kinetics of HCVcc and HCVpp entry demonstrate that CLDN1 mediates 5 
an HCV entry step closely linked to CD81. (A) Schematic drawing of the 
experimental setup. Inhibition of Luc-Jc1 HCVcc entry into Huh7.5.1 cells by heparin 
(250 µg/mL), control monoclonal mouse IgG (5 µg/mL), control rat pre-immune serum 
(1/100), rat anti-CLDN1 serum (1/100), mouse monoclonal anti-CD81 antibody JS-81 
(5 µg/mL) and rat anti-SR-BI serum (1/100) was compared using different protocols 10 
as described in Materials and Methods. Dashed lines indicate the time intervals 
where inhibitors or antibodies were present. All results are expressed as percent Luc-
Jc1 HCVcc infectivity in the absence of inhibitory compound or antibody (CTRL). 
Virus binding to target cells was performed in the presence (protocol I) or absence 
(protocol II) of compounds as described in Materials and Methods. (B) Kinetics of 15 
HCVcc entry into human hepatoma cells by compared protocol I and II. Means ± SD 
of three independent experiments performed in duplicate are shown. (C) Kinetics of 
HCVcc infection into human hepatoma cells in the presence of heparin – an 
attachment inhibitor, anti-CD81 antibody and concanamycin A - an inhibitor of 
endocytosis. Kinetics of HCVcc entry in the presence heparin (●), anti-CD81 (JS-81) 20 
antibody (■), Concanamycin A (♦) (conA; 25nM) or control rat pre-immune serum 
(CTRL) (∆) was determined as described (6, 26, 29, 30). Means of three independent 
experiments performed in triplicate are shown. (D, E) Kinetics of HCVcc entry into 
non-differentiated (D) or DMSO-differentiated (E) Huh7.5.1 cells. The efficiency of 
infection using rat anti-CLDN1 serum (▲), anti-CD81 (JS-81) antibody (■), or control 25 
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rat pre-immune serum (CTRL) (∆) was measured by luciferase assay 48 h later. 
Means of three independent experiments performed in triplicate are shown. (F) 
Kinetics of HCVpp entry in stably transfected 293T/CLDN1+ cells expressing CLDN1 
(as shown in Fig. 1B) using anti-CD81 (JS-81), anti-CLDN1 or control antibodies. 
Means of three independent experiments performed in triplicate are shown.  5 
 
Fig. 6. Dose-dependent inhibition of E2 binding to permissive cell lines by anti-
CLDN1 antibodies. (A) Binding of recombinant E2 glycoprotein to permissive 
Huh7.5.1 cells. Huh7.5.1 cells were pre-incubated with control rat pre-immune serum 
(black lined histograms) or rat anti-CLDN1 antibodies (blue lined histograms) diluted 10 
1/100 for 1 h at RT. Binding of E2 was detected by flow cytometry as described in 
Materials and Methods. Cells incubated in the absence of antibody and E2 (PBS) 
served as negative control (“NC” – light shaded histograms). A representative 
experiment is shown. (B) Binding of recombinant E2 glycoprotein to permissive 
Huh7.5.1 cells. Huh7.5.1 cells were pre-incubated with rat anti-CD81, rat anti-SR-BI 15 
and rat anti-CLDN1 antibodies or control rat pre-immune serum (all diluted 1/100) for 
1 h at RT. Binding of E2 was detected by flow cytometry as described in Materials 
and Methods. Results are expressed as percent E2 binding in the absence of 
antibody (PBS). Means ± SD of four independent experiments performed in duplicate 
are shown. (C) Dose-dependent inhibition of E2 binding to Huh7.5.1 cells by anti-20 
CLDN1. Huh7.5.1 cells were pre-incubated with different dilutions of anti-CLDN1 (■) 
antibodies or control rat pre-immune serum (♦). Results are expressed as percent E2 
binding in the absence of antibody. Means ± SD of four independent experiments 
performed in duplicate are shown. (D) Binding of recombinant E1 glycoprotein to 
permissive Huh7.5.1 cells. Huh7.5.1 cells were pre-incubated with heparin, mouse 25 
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anti-CD81 (JS-81; 5 µg/mL), control mouse IgG (5 µg/mL), rat anti-CLDN1 (1/100), 
rat pre-immune serum (1/100) for 1 h at RT. Binding of E1 was detected by flow 
cytometry as described (6, 26, 29). Results are expressed as percent E1 binding in 
the absence of antibody (PBS). Means ± SD of two independent experiments 
performed in duplicate are shown. (E) Binding of recombinant E2 glycoprotein to rat 5 
BRL-3A cells stably expressing human SR-BI, CD81 and CLDN1 (24). Cells were 
pre-incubated with mouse anti-CD81 (JS-81, 5 µg/mL), control mouse IgG (5 µg/mL), 
rat anti-SR-BI, rat anti-CLDN1 or rat control serum (all diluted at 1/100) and binding 
of E2 was detected using FITC-conjugated anti-His antibody and flow cytometry as 
described in panel (B). Results are expressed as percent E2 binding in the absence 10 
of antibody (PBS). Means ± SD of two independent experiments performed in 
duplicate are shown. (F) Inhibition of HCVcc binding to permissive Huh7.5.1 cells by 
anti-CLDN1. Huh7.5.1 cells were pre-incubated with heparin (250µg/mL), rat anti-
CLDN1 or control (CTRL) serum (all diluted 1/50) for 1 hour at 37°C prior to 
incubation with HCVcc (Jc1 strain) which had been partially purified from cell culture 15 
supernatants using gradient ultracentrifugation. Following incubation with HCVcc, 
non-bound HCVcc were removed by washing of cells with PBS. Binding of HCVcc 
was then quantified by RT-PCR of cell bound HCV RNA as described (11) which is 
indicated on the y-axis. Means ± SD of five independent experiments performed in 
triplicate are shown. *** P < 0.0001. 20 
 
Fig. 7. Cellular binding of envelope glycoprotein E2 to CHO cells expressing 
CD81 and SR-BI but not CLDN1. (A) Expression of human entry factors in 
transfected CHO cell. CHO cells were transfected with expression plasmids encoding 
human CLDN1, SR-BI or CD81 as described in Materials and Methods. Transfected 25 
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CHO cells were analyzed by flow cytometry using rat control (CTRL), rat anti-CLDN1 
(left panel), rat anti-SR-BI (middle panel) or mouse control IgG and anti-CD81 (JS-
81; right panel) (B) Binding of envelope glycoprotein E2 to CHO cells expressing 
human HCV entry factors. CHO cells were transfected with individual expression 
plasmids encoding for human CLDN1, SR-BI or CD81 as indicated. Cellular E2 5 
binding was analyzed by flow cytometry as described (31). A representative 
experiment performed in duplicate is shown. 
 
Fig. 8. Anti-CLDN1 inhibition of CD81-CLDN1 co-receptor association using 
FRET analysis. 293T cells co-transfected to express AcGFP-CD81 and DsRED-10 
CD81, AcGFP-CLDN1 and DsRED-CD81, or AcGFP-CLDN1 and DsRED-CLDN1 
were seeded onto glass coverslips and treated with pre-immune or anti-CLDN1 sera 
for 1 h. Cells were fixed, imaged by laser scanning confocal microscopy and FRET 
between AcGFP donor and DsRED acceptor proteins measured. % FRET is defined 
as the frequency of pixels demonstrating FRET relative to the total number of pixels 15 
analyzed at the plasma membrane of ten cells. *** P < 0.0001, * P < 0.01. AcGFP-
CLDN1 and DsRED-CD81 at intracellular (black) and plasma membrane (white) 
locations in untreated and anti-CLDN1 treated cells were quantified and the 
percentage of CLDN1 at each location determined. 
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Table 1. Anti-CLDN1 antibody reactivity with members of the human CLDN 
family. 293T cells were transfected with plasmids encoding a panel of AcGFP 
tagged human CLDNs (1, 4, 6, 7, 9, 11, 15, 17) and CLDN7/1 chimeric proteins, 
where the N-terminal third (N1/3), half (N1/2) or C-terminal half (C1/2) of EL1 or the 
entire EL2 is replaced with the corresponding coding region of CLDN1 as described 5 
in (9). The frequency of cells expressing AcGFP-CLDN and binding anti-CLDN1 
antiserum was determined by flow cytometry. Data are presented as the frequency of 
AcGFP-CLDN positive cells and their reactivity with anti-CLDN1 serum relative to 
mock transfected cells. 
 10 
AcGFP CLDN 
expression construct 
Frequency of AcGFP 
CLDN positive cells 
(%) 
Frequency of anti-
CLDN1 positive cells  
(%) 
Mock 0 0 
CLDN1 51.3 47.5 
CLDN4 53.7 1.14 
CLDN6 18.4 0.27 
CLDN7 46.6 0.91 
CLDN9 21.8 0.41 
CLDN11 38.2 0.52 
CLDN15 27.5 0.42 
CLDN17 24.4 3.4 
CLDN7/1 N1/3 26.1 16.7 
CLDN7/1 N1/2 12.6 7.33 
CLDN7/1 C1/2 14.5 0.29 
CLDN7/1 EL2 27.6 7.1 
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Table 2. Half-maximal times (t1/2) required for heparin, concanamycin A and 
anti-receptor antibodies to inhibit HCVcc entry in kinetic studies. Half-maximal 
times t1/2 derived from kinetic assays shown in Fig. 5 are indicated. Values are 
means from three independent experiments ± SD. Student’s t-test was used to 
analyze differences in t1/2 for heparin, CD81 and concanamycin A compared to t1/2 for 5 
anti-CLDN1 antibodies. A P value of <0.05 was considered statistically significant. 
 
Compound Half-maximal time 
 (min)  
Significance 
 (P-value)  
Heparin -60 ± 0 <0.05 
Anti-CD81 (JS-81) +30 ± 10 0.643 
Anti-CLDN1 +33 ± 6 reference 
Concanamycin A +60 ± 10 <0.05 
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Inhibition of hepatitis C virus infection by anti-Claudin antibodies is 
mediated by neutralization of E2-CD81-Claudin 1 association(s) 
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ABSTRACT 
The tight junction protein claudin-1 (CLDN1) has been shown to be essential 
for hepatitis C virus (HCV) entry – the first step of viral infection. Due to the 
lack of neutralizing anti-CLDN1 antibodies, the role of CLDN1 in the viral entry 
process is poorly understood. In this study, we produced antibodies directed 5 
against the human CLDN1 extracellular loops by genetic immunization and 
used these antibodies to investigate the mechanistic role of CLDN1 for HCV 
entry in an infectious HCV cell culture system and human hepatocytes. 
Antibodies specific for cell surface expressed CLDN1 specifically inhibit HCV 
infection in a dose-dependent manner. Antibodies specific for CLDN1, 10 
scavenger receptor B1 and CD81 show an additive neutralizing capacity 
compared to when either agent was used alone. Kinetic studies with anti-
CLDN1 and anti-CD81 antibodies demonstrate that HCV interaction(s) with both 
entry factors occur at a similar time in the internalization process. Anti-CLDN1 
antibodies inhibit the binding of envelope glycoprotein E2 to HCV permissive 15 
cell lines in the absence of detectable CLDN1-E2 interaction. Using fluorescent 
labelled entry factors and fluorescence resonance energy transfer (FRET) 
methodology, we demonstrate that anti-CLDN1 antibodies inhibit CD81-CLDN1 
association. In contrast, CLDN1-CLDN1 and CD81-CD81 associations were not 
modulated. Taken together, our results demonstrate that antibodies targeting 20 
CLDN1 neutralize HCV infectivity by reducing E2 association with the cell 
surface and disrupting CD81-CLDN1 interactions. In conclusion, these results 
further define the function of CLDN1 in the HCV entry process and highlight 
new antiviral strategies targeting E2-CD81-CLDN1 interactions. 
 25 
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INTRODUCTION 
With an estimated 170 million infected individuals, hepatitis C virus (HCV) has a 
major impact on public health. HCV is a hepatotropic virus that causes persistent 
infection in the majority of infected individuals (1). Therapeutic options for chronic 
infection are limited and a vaccine is not available (2). 5 
 
HCV entry into hepatocytes is the first step of the viral life cycle resulting in 
productive viral infection (3, 4). Furthermore, HCV entry is a major target of host 
neutralizing responses (5-7) and a target for antiviral immunopreventive and 
therapeutic strategies (for review see (4, 8)). Viral entry is believed to be mediated by 10 
the viral envelope glycoproteins E1 and E2 and several host entry factors. These 
include heparan sulfate, tetraspanin CD81, scavenger receptor class B type I (SR-BI) 
(3) and the tight junction (TJ) proteins claudin-1 (CLDN1) (9) and occludin (10, 11). 
As none of these host cell surface factors alone is able to promote HCV entry, the 
interaction of HCV and its target cells leading to the internalization of the virus is 15 
believed to be a multistep process involving the interplay of several host cell factors 
(3, 4, 8). 
 
Evans and colleagues reported that CLDN1 is essential for HCV infection (9). 
Subsequent studies demonstrated that CLDN-6 and -9 are also able to mediate HCV 20 
entry in non permissive cell lines (12, 13). CLDNs are critical components of TJs that 
regulate paracellular permeability and polarity and have a tetraspanin topology with 
four transmembrane domains, two extracellular and one intracellular loops, and N- 
and C-terminal cytoplasmic domains (14). CLDN1 extracellular loop 1 (EL1) is 
required for HCV entry (9) and is involved in barrier function and contributes to pore 25 
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formation between polarized cells (15). Mutagenesis studies in non-polarized 293T 
cells demonstrate that CLDN1 enrichment at cell-cell contacts may be important for 
HCV entry (16). We (17, 18) and others (16, 19, 20) using a variety of imaging and 
biochemical techniques reported that CLDN1 associates with CD81. However, due to 
the lack of neutralizing anti-CLDN1 antibodies targeting extracellular epitopes, the 5 
exact role of CLDN1 in the viral entry process is poorly understood. 
 
In this study, for the first time we produced anti-CLDN1 antibodies that bound 
to cell surface expressed CLDN1 and inhibited HCV infection. The anti-CLDN1 
antibodies inhibit HCV E2 glycoprotein interaction with permissive hepatoma cells 10 
and fluorescence resonance energy transfer (FRET) between CD81-CLDN1 co-
receptor complexes supporting a model where CLDN1 potentiates CD81 interaction 
with the virus and facilitates particle internalization. 
.
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MATERIALS AND METHODS 
Cells. Human Huh7 (5), Huh7.5.1 (21), HepG2 (18), 293T (5), Bosc (22), Caco-2 
(23), and rat BRL-3A hepatocyte-derived cell lines (24) were propagated in 
DMEM/10% foetal bovine serum. 293T/CLDN1 cells were obtained by stable 
transfection of 293T cells with a pcDNA3.1 vector encoding CLDN1 cDNA. DMSO-5 
mediated differentiation of Huh7.5.1 cells was performed as described (25). Primary 
human hepatocytes were isolated from liver resections from patients at the 
Strasbourg University Hospitals with approval from the Institutional Review Board 
(26, 27). In brief, liver specimen were perfused with calcium-free HEPES buffer 
supplemented with 0.5 mM EGTA (Fluka) followed by perfusion with HEPES buffer 10 
supplemented with 0.05% collagenase (Sigma) and 0.075% CaCl2 at 37°C. Following 
washing of cells with PBS and removal of nonviable cells by Percoll (Sigma) gradient 
centrifigation, freshly isolated hepatocytes (3 x 105 cells/well) were plated in 24-well-
plates pre-coated with collagen (Biocoat, BD Biosciences) and allowed to adhere in 
William’s E medium (Sigma Aldrich) containing 1 % Glutamax (Gibco), 1 % ITS 15 
(insulin transferrin selenium Gibco), 10–7 M dexamethasone (Sigma), 0.15% bovine 
serum albumine (Sigma) and 10% fetal calf serum (PAN Biotec). 
 
Antibodies. Anti-CLDN1 antibodies were raised by genetic immunization of Wistar 
rats using a human CLDN1 cDNA expression vector. For screening, Bosc cells 20 
transfected with pCMV-SPORT6 or pCMV-SPORT6/CLDN1 were incubated with 
anti-CLDN1 or pre-immune serum and analyzed for cell surface CLDN1 expression 
by flow cytometry as described (28). Purified IgG from rat anti-CLDN1 serum were 
obtained by MAbTrapTM kit (GE Healthcare). To analyze cross-reactivity of antibodies 
with other members of the CLDN family, 293T cells were transfected to express 25 
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 7 
AcGFP tagged CLDN1, 4, 6, 7, 9, 11, 15 and 17 or chimeric CLDN1/7 (described in 
(9)) and 48 h later stained with rat anti-CLDN1 antibodies and Alexa-633 coupled 
anti-Rat Ig (Invitrogen). Cells were imaged by flow cytometry and data analyzed by 
FLowJo. Polyclonal rat anti-SR-BI or CD81 antibodies were obtained by genetic 
immunization as described (26). R-phycoerythrin-conjugated and Cy5-conjugated 5 
anti-rat IgG were from Jackson ImmunoResearch Laboratories, mouse IgG from 
Caltag, mouse anti-CD81 (JS-81) from BD Biosciences. 
 
Imaging studies of cell surface CLDN1. Living Huh7.5.1 cells were incubated with 
pre-immune or anti-CLDN1 serum (1/50) and a Cy5-conjugated anti-rat secondary 10 
antibody (1/300; Jackson ImmunoResearch). Polarized Caco-2 cells, as described in 
(23), were fixed in 3% paraformaldehyde, permeabilized with saponin and stained 
with polyclonal anti-CLDN1 (1/50) or control serum. Following staining, cells were 
fixed, mounted and observed using a Leica TCS SP2 CLSM (for Huh7.5.1) or a Zeiss 
Cell Axio Observer Z1 microscope (for Caco-2). 15 
 
Determination of tight junction barrier function. To determine the functionality of 
TJs and whether they restrict the paracellular diffusion of solutes from the bile-
canalicular (BC) lumen to the basolateral medium (barrier function), HepG2 cells 
were treated with either control (PBS), rat anti-CLDN1, rat control serum or IFNγ and 20 
incubated with 5 mM 5-chloromethylfluorescein diacetate (CMFDA; Invitrogen) at 
37°C for 10 minutes to allow internalization and translocation to BC lumen by MRP2. 
After washing with PBS, the capacity of BC lumens to retain CMFDA was analyzed 
as described (18). 
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HCVcc production and infection. HCVcc (Luc-Jc1 or Jc1 strains) were generated 
as described (6, 26, 29). For infection experiments, Huh7.5.1 cells were pre-
incubated in the presence or absence of antibodies for 1 h at 37°C and infected at 
37°C for 4 h with HCVcc. 48 h later HCV infection was analyzed in cell lysates by 
quantification of luciferase activity or viral RNA (6, 26, 29, 30). Kinetic studies in the 5 
presence of antibodies or inhibitors were performed as described (6, 26, 29, 30).  
 
HCV pseudoparticle (HCVpp) production and infection. Infection of 293T/CLDN1 
or Huh7.5.1 cells with MLV-based HCVpp in kinetic assays was performed as 
described (5, 6). Primary hepatocytes were infected with HIV-based HCVpp 10 
expressing envelope glycoproteins of strains HCV-J (genotype 1b), JFH-1 (genotype 
2a), UKN3A.1.28 (genotype 3a) and UKN4.21.16 (genotype 4) (described in (5)) 
containing a luciferase reporter element. One day following hepatocyte isolation and 
plating, hepatocytes were washed with PBS and pre-incubated with rat anti-CLDN1 
or control serum (1/50) for 1 hour at 37°C in William’s E medium. Then, HCVpp were 15 
added for 3 hours at 37°C. Following infection, the supernatant was removed and 
replaced by fresh William’s E medium. HCVpp infection was assessed by 
measurement of luciferase activity 72 hours post-infection as described (6, 26). 
 
Cellular binding of HCV envelope glycoproteins E1 and E2. Production and 20 
binding of C-terminally truncated envelope glycoproteins has been described (6, 24). 
For the study of E2-entry factor interaction, CHO cells were transfected with pcDNA3 
based expression vectors encoding SR-BI, CD81 or CLDN1 as described (31). 
Expression of entry factors was assessed by flow cytometry using anti-receptor 
antibodies as described (31). For the study of envelope glycoprotein binding in the 25 
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 9 
presence of anti-receptor antibodies, Huh7.5.1 cells (21) or rat BRL-3A cells stably 
expressing human SR-BI, CD81 and CLDN1 (24) were pre-incubated 1 h at RT with 
rat anti-SR-BI, -CLDN1, -CD81 serum (1/100) or mouse anti-human CD81 (JS-81; 5 
µg/mL) or control antibodies (1/100 or 5 µg/mL). Recombinant E2 (30 µL cell culture 
supernatant) or E1 (10 µg/mL) was added to cells for 1 h at RT. Following washing 5 
with PBS, bound envelope glycoproteins were detected using flow cytometry and 
human anti-E1 (IGH526 (6)) or mouse anti-His (RGS-His, Qiagen) and PE-
conjugated secondary antibodies (24, 28). For quantitation of HCVcc binding, 
Huh7.5.1 cells were pre-incubated with heparin (250µg/mL), rat anti-CLDN1 (1/50) or 
control serum (1/50) for 1 hour at 37°C prior to incubation with HCVcc (Jc1 strain) 10 
which had been partially purified from cell culture supernatants using sucrose 
gradient ultracentrifugation. Following incubation with HCVcc, non bound HCVcc 
were removed by washing of cells with PBS. Binding of HCVcc was then quantified 
by RT-PCR of cell bound HCV RNA as described (9). 
 15 
Receptor association using fluorescence resonance energy transfer (FRET). 
Homotypic and heterotypic interactions of CD81 and CLDN1 were analyzed as 
described (17, 18). Briefly, 293T cells transduced to express AcGFP and DsRED 
tagged CD81 and CLDN1 were grown on glass coverslips and fixed in ice-cold 
methanol. The cells were imaged on a Zeiss meta head LSCM, with microscope 20 
settings optimized for each fluorescent protein to obtain the highest signal-to-noise 
ratio. For FRET analysis, the gradual acceptor photobleaching method of FRET was 
used, which entailed photobleaching the DsRED fluorophore gradually over time 
while monitoring AcGFP fluorescent intensity (17). After background and cross-talk 
correction, any increase in AcGFP intensity following DsRED photobleaching is due 25 
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to FRET between proteins, implying a distance of less than 10 nm. The percent 
FRET is defined as the number of pixels that display FRET over the total number of 
pixels analyzed at the plasma membrane of the cells (17). The data from 10 cells 
were normalized and the localized expression calculated. 
 5 
Statistical analysis. Results are expressed the mean ± standard deviation (SD). 
Statistical analyses were performed using Student's t test with a P value of <0.05 
being considered statistically significant. 
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RESULTS 
Production of antibodies directed against cell surface CLDN1. To investigate the 
role of CLDN1 in HCV infection, we produced polyclonal anti-CLDN1 antibodies by 
genetic immunization and screened for reactivity with cell surface expressed CLDN1. 
Antibodies were selected for their ability to bind non-permeabilized Bosc cells 5 
transfected to express human CLDN1. Bosc cells are 293T-derived ecotropic 
packaging cells (22) which do not express endogenous CLDN1 (data not shown). As 
shown in Fig. 1A, incubation of Bosc cells expressing human CLDN1 with polyclonal 
anti-CLDN1 sera resulted in a specific interaction with CLDN1 extracellular domains 
(Fig. 1A). To confirm the specific interaction of anti-sera with CLDN1 we generated 10 
293T cells stably expressing human CLDN1 (Fig. 1B). Incubation of 293T/CLDN1 
cells with rat polyclonal anti-CLDN1 antibodies resulted in a specific interaction of 
these antibodies with human CLDN1 (Fig. 1B). These data demonstrate that anti-
CLDN1 antibodies obtained by genetic immunization specifically bind to the 
extracellular loops of human CLDN1 expressed on the cell surface. Using 293T cells 15 
transfected with tagged AcGFP tagged CLDN1, 4, 6, 7, 9, 11, 15 and 17 or chimeric 
CLDN1/7, we show that anti-CLDN1 antibodies demonstrate minimal or absent 
cross-reactivity against other members of the CLDN family (Table 1). 
  
Analysis of anti-CLDN1 reactivity to chimeric CLDN1/7 expressed on the cell 20 
surface of 293T cells demonstrated that the antibodies interact strongly with CLDN7 
where the N-terminal third (N1/3) or half (N1/2) was replaced with the corresponding 
coding region of CLDN1 (Table 1). In contrast, the antibodies did not exhibit any 
detectable interaction with CLDN7 where the C-terminal half (C1/2) of EL1 was 
replaced with the corresponding coding region of CLDN1. A reduced interaction was 25 
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observed for CLDN7 expressing the entire EL2 of CLDN1 (Table 1). These data 
demonstrate that anti-CLDN1 antibodies recognize epitopes in the N-terminal half of 
the CLDN1 EL1 which has been shown to be required for HCV entry (9) as well as 
EL2 epitopes (Table 1). Since antibodies failed to recognize overlapping peptides 
encoding for linear epitopes comprising the CLDN1 EL1 and 2 in an ELISA or an 5 
infection assay using peptides as capture antigens (data not shown), it is likely that 
epitopes targeted by anti-CLDN1 antibodies are conformation-dependent. 
 
To study whether anti-CLDN1 antibodies bind to CLDN1 on the cell surface of 
HCV permissive cells, Huh7.5.1 and primary human hepatocytes were incubated with 10 
anti-CLDN1 and analyzed by flow cytometry. Positive staining of human Huh7.5.1 
hepatoma cells and human hepatocytes with polyclonal anti-CLDN1 antibodies in the 
absence of permeabilizing reagents demonstrated that these antibodies bind to 
CLDN1 expressed on the surface of primary hepatocytes and HCV permissive cell 
lines (Fig. 1C). To further address the specificity of antibodies, we performed CLDN1 15 
knock-down experiments in Huh7.5.1 cells using a pool of three siRNAs described by 
Evans et al. (9). CLDN1 silencing resulted in a decrease of anti-CLDN1 staining in 
immunoblot analyses (data not shown) further confirming the specificity of the 
antibodies. 
 20 
Positive staining of native cell surface CLDN1 in living, non-permeabilized 
Huh7.5.1 cells with anti-CLDN1 antibodies was confirmed using imaging studies. 
Interestingly, in living native Huh7.5.1 cells, the antibody appeared to localize to 
certain areas of cell-cell contact (Fig. 1D), whereas in permeabilized Huh7.5.1 or 
Caco-2 cells antibody staining showed a polygonal web-like structure (Fig. 1D) which 25 
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was similar to previous studies using non-neutralizing anti-CLDN1 antibodies (23). 
CLDN1 staining appeared to be more pronounced in polarized Caco-2 cells than in 
non-polarized Huh7.5.1 cells (Fig. 1D). Further imaging studies are ongoing to 
determine the detailed subcellular localization of CLDN1 recognized by neutralizing 
anti-CLDN1 antibodies in HCV permissive cells.  5 
 
Taken together, these data demonstrate that anti-CLDN1 serum produced by 
genetic immunization specifically binds to the CLDN1 extracellular loops expressed 
on the cell surface of HCV permissive cell lines and human hepatocytes. 
 10 
Anti-CLDN1 antibodies do not affect tight-junction integrity. We previously 
reported that TJs impose a physical barrier and restrict viral access to receptors (23) 
and that complex hepatocyte-like polarity limits HCV entry (18). To investigate 
whether binding of anti-CLDN1 antibodies to polarized human hepatoma cells 
perturbed TJ integrity, we assessed the ability of TJs to restrict the paracellular 15 
diffusion of 5-chloromethylfluorescein diacetate (CMFDA) from the bile-canalicular 
(BC) lumen to the basolateral medium (barrier function) as previously described (18). 
As shown in Fig. 2, the capacity of BC lumens to retain CMFDA was similar in 
polarized HepG2 cells treated with rat anti-CLDN1 antibodies, rat control serum or 
PBS whereas CMFDA retention was reduced in IFNγ-treated HepG2 cells (Fig. 2B). 20 
These data suggest that anti-CLDN1 antibodies have no effect on TJ integrity.  
 
Neutralization of HCV infection by anti-CLDN1 antibodies. To investigate whether 
anti-CLDN1 antibodies could inhibit HCV infection, Huh7.5.1 cells were infected with 
chimeric J6/CF-JFH1 firefly luciferase reporter virus (Luc-Jc1) (26, 29) in the 25 
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presence of anti-CLDN1 or control antibodies. Fig. 3A shows that anti-CLDN1 serum 
inhibits Luc-Jc1 infection of Huh7.5.1 cells in a dose-dependent manner whereas the 
control pre-immune serum had no inhibitory effect. Neutralization of HCVcc infection 
correlated with binding of antibodies to the target cell line (Fig. 3B). To confirm that 
inhibition of Luc-Jc1 infection was mediated by anti-CLDN1 antibodies, we purified 5 
IgG from rat anti-CLDN1 and pre-immune serum. As shown in Fig. 3C, anti-CLDN1 
IgG but not control IgG markedly inhibited Luc-Jc1 HCVcc infection in a dose-
dependent manner. These data demonstrate that the inhibitory effect of anti-CLDN1 
serum was mediated by anti-CLDN1 IgG and not by other substances present in the 
serum. Infection experiments using primary human hepatocytes and HCVpp 10 
packaged with envelope glycoproteins from genotypes 1-4 demonstrated that anti-
CLDN1 blocking activity was similar for infection with HCV bearing envelope proteins 
of other genotypes (Fig. 3D). Taken together, these findings demonstrate that 
antibodies directed against the CLDN1 extracellular loops inhibit HCV infection in 
HCV permissive cell lines and human hepatocytes. 15 
 
CLDN1 acts cooperatively with CD81 and SR-BI in HCV entry. We previously 
demonstrated that CD81 and SR-BI act in concert to mediate HCV entry (26). To 
investigate whether the three host factors CLDN1, CD81 and SR-BI act in a 
cooperative manner, we added low concentrations of anti-receptor antibodies 20 
simultaneously prior to HCV infection. The use of antibody concentrations that sub-
maximally blocked HCV infection allowed us to observe additive or synergistic 
effects. First, we determined the ability of combinations of two out of the three 
antibodies to neutralize HCVcc infection. Fig. 4 shows an additive effect of the 
concomitant blocking of both CD81 and CLDN1 (Fig. 4B), SR-BI and CLDN1 (Fig. 25 
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4C) or CD81 and SR-BI (Fig. 4D). This effect was not observed when control IgG or 
control serum was used in combination with anti-CLDN1 antibodies (data not shown). 
Next, we assessed the impact of synchronously blocking all three host cell factors on 
HCVcc infection. Fig. 4E shows an additive effect of the three antibodies used. 
Indeed, Luc-Jc1 HCVcc infection was inhibited by more than 90% after simultaneous 5 
blocking of three host cell factors at antibody concentrations that inhibited HCVcc 
infection between 15% and 60% when used individually. Taken together, these 
results suggest that CLDN1 mediates HCV entry in cooperation with CD81 and SR-
BI. 
 10 
CLDN1 mediates an HCV entry step closely linked to HCV-CD81 interaction. To 
investigate the role of CLDN1 in the entry process, we investigated the inhibitory 
capacity of anti-CLDN1 antibodies in kinetic studies (26, 29). To discriminate 
between virus binding and post-binding events, Luc-Jc1 HCVcc binding to Huh7.5.1 
cells was performed for 1 h at 4°C in the presence or absence of inhibitors before the 15 
temperature was shifted to 37°C to initiate synchronous infection (Fig. 5A). Fig. 5B 
shows that similarly to anti-CD81 and anti-SR-BI, rat anti-CLDN1 inhibited Luc-Jc1 
HCVcc infection when added following binding of the virus to the target cell (Fig. 5B). 
To fine-map the entry step mediated by CLDN1, we added antibodies in side-by-side 
experiments every 20 min for up to 120 min after viral binding (Fig. 5C). The half-20 
maximal times (t1/2) required for anti-CD81 and anti-CLDN1 antibodies to inhibit HCV 
entry were +30 and +33 minutes (Fig. 5C-E; Table 2), whereas the half-maximal 
times for heparin was –60 minutes and for concanamycin A was +60 minutes (Fig. 
5C; Table 2). The time-course of anti-CLDN1 and anti-CD81-antibody-mediated 
inhibition was not significantly different, and both differed from those observed with 25 
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heparin and concanamycin A (Table 2). Similar results were obtained in DMSO 
differentiated Huh7.5.1 (27) cells (Fig. 5E). These data support a model where 
CLDN1 and CD81 exert their effects at a similar time in the viral internalization 
process. 
 5 
Using Flag-tagged CLDN1 transfected 293T cells, Evans et al. reported that 
anti-Flag inhibition of HCVpp infection occurred at later time points compared to a 
CD81 specific antibody (9). These results differ from those obtained in this study that 
may be attributable to the experimental systems used in the two studies, including: 
293T/CLDN1 versus Huh7.5.1 cell lines, HCVpp versus HCVcc, the strain of HCV 10 
envelope glycoproteins H77 versus J6/JFH1 and the blocking antibodies (anti-
CLDN1 versus anti-Flag). To further address this question, we studied the kinetics of 
anti-CLDN1 and anti-CD81 neutralization of HCVpp infection of 293T/CLDN1. 
Inhibition of HCVpp infection of 293T/CLDN1 cells by anti-CLDN1 and anti-CD81 
demonstrated a similar kinetics (Fig. 5F) to those observed for HCVcc infection of 15 
Huh7.5.1 cells (Fig. 5D, E). Thus, the different kinetic results described by Evans et 
al. and us are most likely not related to the experim ntal model system but rather 
related to the insertion of a Flag tag into CLDN1 (9). 
 
Anti-CLDN1 inhibits binding of envelope glycoprotein E2 to HCV 20 
permissive cells in the absence of CLDN1-E2 interactions. Next, we investigated 
whether anti-CLDN1 antibodies could interfere with E2 binding to permissive cell 
lines. Binding studies were performed using recombinant E1 and E2 glycoproteins in 
the presence of anti-receptor or control antibodies. As shown in Fig. 6B, anti-CD81, 
anti-SR-BI and anti-CLDN1 antibodies inhibited the binding of E2 to Huh7.5.1 cells. 25 
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In contrast, pre-immune or unrelated control serum had no effect (Fig. 6A-C). Similar 
results were obtained for antibody inhibition of E2 binding to BRL-3A rat hepatocyte-
derived cells engineered to express the three human entry co-factors, SR-BI, CD81 
and CLDN1 (24) (Fig. 6E). Expression of SR-BI, CD81 and CLDN1 on the cell 
surface of stably transfected BRL-3A cells was confirmed by flow cytometry and 5 
expression levels were comparable to Huh7 cells (data not shown and (24)). 
Interestingly, the magnitude of inhibition of E2 binding to Huh7.5.1 cells (Fig. 6C) 
correlated with the magnitude of inhibition of HCV infection (Fig. 3B), suggesting that 
inhibition of binding of E2-cell surface interactions provides a mechanism of action for 
the neutralizing activity of the anti-CLDN1 antibodies. In contrast, E1 binding was not 10 
affected by anti-CLDN1 (Fig. 6D). To investigate whether inhibition of E2 binding 
resulted in an inhibition of binding of infectious virions, we studied cellular binding of 
Jc1 HCVcc in the presence of anti-CLDN1 antibodies. Although HCVcc binding 
analyses were characterized by a higher inter-assay variability compared to E2 
binding studies, anti-CLDN1 antibodies markedly and significantly inhibited HCVcc 15 
binding to Huh7.5.1 cells (Fig. 6F). 
 
To study whether antibody inhibition of E2 binding to permissive cell lines was 
attributable to CLDN1 interactions with E2 we investigated whether CLDN1 was able 
to bind recombinant truncated glycoprotein E2. To address this question CHO cells 20 
were engineered to express human CLDN1, SR-BI or CD81 (Fig. 7A). Cell surface 
expression of human CD81 or human SR-BI conferred E2 binding to CHO cells (Fig. 
7B), whereas CLDN1 expression had no effect (Fig. 7B). These data suggest that 
CLDN1 does not interact directly with HCV envelope glycoprotein E2 and that 
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antibody blocking of E2-cell surface interactions may be mediated by indirect 
mechanisms. 
 
Anti-CLDN1 antibodies inhibit CLDN1-CD81 co-receptor association(s). Since 
anti-CLDN1 inhibits E2 binding to HCV permissive cells in the absence of a direct 5 
CLDN1-E2 interaction (Fig. 7B), we hypothesized that anti-CLDN1 antibodies may 
interfere with CD81-CLDN1 co-receptor complexes. To assess whether anti-CLDN1 
alter CLDN1-CD81 association, 293T cells were transfected to express AcGFP-CD81 
and DsRED-CD81 or AcGFP-CLDN1 and DsRED-CD81 or AcGFP-CLDN1 and 
DsRED-CLDN1 (17), incubated with pre-immune and anti-CLDN1 serum (1/100 and 10 
1/400) and co-receptor interaction(s) analyzed by FRET. As shown in Fig. 8, anti-
CLDN1 antibodies significantly reduced FRET between CD81 and CLDN1 in a dose-
dependent manner. Pre-incubation of cells with control serum did not modify CD81-
CLDN1 co-receptor interaction(s). Inhibition of CD81-CLDN1 co-receptor interaction 
was specific as shown by the unchanged FRET between CD81-CD81 and CLDN1-15 
CLDN1 following pre-incubation with anti-CLDN1 serum. Taken together, these data 
suggest that anti-CLDN1 antibodies interfere with CD81-CLDN1 heterodimer 
association. 
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DISCUSSION 
For the first time we report the genesis and characterization of antibodies directed 
against the extracellular loops of human CLDN1 which inhibit HCV infection. CLDN1 
showed no evidence for a direct association with the viral envelope E1E2 
glycoproteins and yet anti-CLDN1 serum inhibited E2 association with the cell 5 
surface and disrupted CD81-CLDN1 interactions. These data suggest a role for 
CD81-CLDN1 complexes in viral entry and highlight new antiviral strategies targeting 
co-receptor complex formation. 
 
CLDN1 is an essential co-factor conferring HCV entry (9), however, the 10 
precise role of CLDN1 in the multi-step entry process remains poorly understood. 
Using antibodies directed against CLDN1 EL, we demonstrate a dose-dependent 
inhibition of viral envelope association with HCV permissive cell lines. Using 
transfected CHO cells expressing human HCV entry factors, we demonstrate that in 
contrast to CD81 and SR-BI, CLDN1 does not directly interact with envelope 15 
glycoprotein E2 at the cell surface.  
 
Using a recent FRET-based system to study CD81-CLDN1 co-receptor 
association (17), we demonstrate that neutralizing anti-CLDN1 antibodies specifically 
disrupt CD81-CLDN1 FRET (Fig. 8). These data suggest that CD81-CLDN1 co-20 
receptor complexes are critical for HCV entry and CLDN1 may potentiate CD81 
association with HCV particles via E2 interactions. The functional relevance of the 
CD81-CLDN1 co-receptor complex for HCV entry is further corroborated by kinetic 
studies demonstrating that CD81 and CLDN1 act at a similar time point during HCV 
entry (Fig. 5). Although the magnitude of antibody-mediated inhibition of HCVcc 25 
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infection was slightly different, the kinetics of inhibition by anti-CLDN1 and anti-CD81 
were similar (Fig. 5C-F and Table 2).  
 
Using a HCVpp kinetic assay in 293T cells expressing Flag-tagged CLDN1 
and anti-Flag antibody, Evans et al. observed anti-Flag antibody inhibition of HCVpp 5 
infection at a later time point than anti-CD81, suggesting that CLDN1 has a role in 
late stages of the viral internalization process (9). Evans et al., reported that the 
inhibitory activity of anti-CD81 antibody was lost much earlier than the anti-Flag 
antibody (half-maximal inhibition at 18 and 73 min post temperature shift, 
respectively). However, we observed a loss of anti-CLDN1 and anti-CD81 inhibitory 10 
activity at similar times (half-maximal inhibition for both antibodies at +30 and +33 
min post temperature shift respectively). Comparable results using HCVpp infection 
of 293T/CLDN1 cells (Fig. 5F) suggest that the differences between the two studies 
relate to the inserted Flag epitope in CLDN1 sequence or the use of an anti-Flag 
antibody. It is conceivable that insertion of a triple Flag epitope into CLDN1 EL1 (9) 15 
may alter CLDN1 trafficking and possible association with CD81 resulting in a 
delayed inhibition of infection by anti-Flag antibody (9) compared to antibodies 
targeting native CLDN1. We conclude that CLDN1 and CD81 entry factors act in a 
cooperative manner in a closely linked step during HCV entry, consistent with earlier 
reports on CD81-CLDN1 association (17-19). 20 
 
Taken together, our findings support a model in which viral attachment and 
interaction with glycosaminoglycans and SR-BI promote or facilitate viral interaction 
with CD81-CLDN1 complexes. Since anti-CLDN1 inhibit envelope glycoprotein E2 
and virion binding to permissive cells in the absence of any detectable CLDN1-E2 25 
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interactions, it is conceivable that CLDN1 association with CD81 enhances viral 
glycoprotein association(s) to the HCV co-receptor complex that are required for 
virus internalization. These results define the function of CLDN1 in the HCV entry 
process and highlight new antiviral strategies targeting E2-CD81-CLDN1 interactions. 
 5 
The development of neutralizing anti-CLDN1 antibodies may provide new 
therapeutic options for the prevention of HCV infection. Our data clearly demonstrate 
that CLDN1 is a target for HCV therapeutic intervention that may complement 
ongoing efforts to block intracellular replication events with inhibitors of the HCV 
proteases and polymerase (9). The observation that anti-CLDN1 had no effect on 10 
HepG2 permeability and TJ integrity (Fig. 2) merits further investigation into the use 
of anti-CLDN1 antibodies as a therapeutic for HCV infection. The production of 
antibodies directed against HCV entry factors such as CLDN1 may widen the future 
preventive and therapeutic strategies for HCV infection and ultimately be used for the 
prevention of HCV infection following needle stick injury or during liver 15 
transplantation. Further efforts are underway to produce monoclonal anti-CLDN1 
antibodies for that strategy. 
 
In conclusion, our results suggest that viral entry requires the formation of a 
virus-co-receptor complex including HCV E2, CD81 and CLDN1. The functional 20 
mapping of E2-CD81-CLDN1 association and its impact for HCV entry has important 
implications for the understanding of the very first steps of HCV infection and the 
development of novel antiviral strategies targeting viral entry. 
 
 25 
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FIGURE LEGENDS 
Fig. 1. Production of antibodies directed against human CLDN1 extracellular 
domains using genetic immunization. (A) Specific binding of rat anti-human 
CLDN1 serum to CLDN1 expressed on the cell surface of transfected Bosc cells. 
Bosc cells were transfected with pCMV-SPORT6-CLDN1 (red histograms) or control 5 
vector (pCMV-SPORT6; black histograms). Flow cytometry of cells incubated with 
control serum (left panel) or anti-CLDN1 serum (right panel) demonstrated specific 
interaction of anti-CLDN1 antibodies with human CLDN1 (red histograms). The x and 
y axes show mean fluorescence intensities and relative numbers of stained cells, 
respectively. (B) Staining of cell surface CLDN1 on 293T/CLDN1 cells stably 10 
expressing CLDN1 by anti-CLDN1 antibodies. Flow cytometry of 293T/CLDN1 (clone 
IIIA6) cells (red histograms) or 293T parental cells (black histograms) incubated with 
control (left panel) or anti-CLDN1 IgG (right panel) demonstrated specific interaction 
of anti-CLDN1 antibodies with human CLDN1. (C) Cell surface expression of CLDN1 
on hepatoma cells lines or primary hepatocytes was determined by flow cytometry in 15 
the absence of permeabilization. Histograms corresponding to cell surface 
expression of CLDN1 (open curves) are overlaid with histograms of cells incubated 
with rat control serum (black shaded curves). (D) Imaging of cell surface CLDN1 on 
living Huh7.5.1 cells (left panels), permeabilized Huh7.5.1 (middle panels) and Caco-
2 (right panels) cells by anti-CLDN1 antibodies (upper panels). Cells incubated with 20 
control serum are depicted in the lower panels. Cells were incubated with pre-
immune serum or anti-CLDN1 and analyzed as described in Materials and Methods. 
Cell nuclei were stained with DAPI. 
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Fig. 2. Anti-CLDN1 antibody does not alter tight junction integrity in polarized 
HepG2 cells. (A) The bile canalicular (BC) lumen in polarized HepG2 cells was 
assessed for TJ “barrier” function. Cells were incubated with CMFDA, with restriction 
of the compound to the BC indicating that polarized HepG2 cells have functional TJs. 
(B) Polarized HepG2 cells grown for 3 days were treated with serum free DMEM for 5 
4h before being exposed to either control (PBS), irrelevant IgG control (1:100), anti-
CLDN1 Ab (1:100) or 10 ng/mL IFNγ for 1 h. TJ barrier function was measured by 
quantifying the number of BC retaining CMFDA compared to the total BC in a 
minimum of three fields of view on three replicate coverslips. *** P < 0.0001 (t test).  
 10 
Fig. 3. Dose-dependent inhibition of HCVcc infection by anti-CLDN1 antibodies. 
(A) Inhibition of Luc-Jc1 HCVcc infection by rat anti-CLDN1 serum. Huh7.5.1 cells 
were pre-incubated with serial dilutions of rat anti-CLDN1 serum or control rat serum 
for 1 h at 37°C before infection with Luc-Jc1 HCVcc for 4 h at 37°C. HCV infection 
was assessed by measurement of luciferase activity 48 h post-infection. Mean ± SD 15 
from a representative experiment performed in triplicate are shown. (B) Binding of 
anti-CLDN1 antibody to Huh7.5.1 cells. Huh7.5.1 cells were incubated with 
decreasing dilutions of anti-CLDN1 antibody and binding of anti-CLDN1 was 
determined by flow cytometry as described in Fig. 1. (C) Jc1 HCVcc infection in the 
presence of purified rat anti-CLDN1 IgG. Huh7.5.1 cells were pre-incubated for 1 h at 20 
37°C with serial dilutions of IgG isolated from rat anti-CLDN1 or control serum before 
infection with Jc1 HCVcc. 48 h later, HCV infection was analyzed by quantitation of 
HCV RNA using RT-PCR in intracellular lysates. Results are expressed as percent of 
HCVcc infectivity in the absence of antibody. Mean ± SD from a representative 
experiment performed in triplicate are shown. (D) Inhibition of HCVpp infection in 25 
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primary human hepatocytes by anti-CLDN1 antibodies. One day after isolation and 
plating, hepatocytes were washed and pre-incubated with rat anti-CLDN1 or control 
serum (1/50) for 1 hour at 37°C in medium. Then, HIV-based HCVpp bearing 
envelope glycoproteins of strains HCV-J (genotype 1b), JFH-1 (genotype 2a), 
UKN3A.1.28 (genotype 3a) and UKN4.21.16 (genotype 4) were added for 3 hours at 5 
37°C. Following infection, the supernatant was removed and replaced by fresh 
medium. HCVpp infection was assessed by measurement of luciferase activity 72 
hours post-infection. Inhibition of HCVpp infection is shown as % infection compared 
to hepatocytes incubated with control serum (=100%). *** P < 0.0001. 
 10 
Fig. 4. CLDN1, CD81 and SR-BI act in concert to mediate HCVcc entry. (A) Dose-
dependent inhibition of Luc-Jc1 HCVcc infection by anti-CLDN1, anti-CD81, and anti-
SR-BI antibodies. Huh7.5.1 cells were pre-incubated for 1 h at 37°C with control 
mouse IgG (0.1 µg/mL), control rat pre-immune serum (PI) (1/200), anti-CD81 
antibody JS-81 (0.1 and 0.05 µg/mL), rat anti-CLDN1 serum (1/100, 1/200, 1/400) or 15 
rat anti-SR-BI serum (1/200, 1/400, and 1/800) before infection with Luc-Jc1 HCVcc 
for 4 h at 37°C. HCV infection was assessed by measurement of luciferase activity 
48 h post-infection. Data are expressed as percent of Luc-Jc1 HCVcc infectivity in 
the absence of antibody. (B-E) Additive effects of anti-CD81 and anti-CLDN1 (panel 
B), anti-SR-BI and anti-CLDN1 (panel C), anti-CD81 and anti-SR-BI (panel D) and 20 
anti-CD81, anti-CLDN1 and anti-SR-BI antibodies (panel E) resulting in inhibition of 
HCVcc entry. Huh7.5.1 cells were pre-incubated for 1 h at 37°C with rat anti-CLDN1 
(1/200 and 1/400) mouse anti-CD81 JS-81 (0.1 µg/mL and 0.05 µg/mL) and rat anti-
SR-BI (1/400 and 1/800) antibodies either alone (black bars) or in combination before 
infection (grey bars) with Luc-Jc1 HCVcc for 4 h at 37°C. HCV infection was 25 
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assessed as described in (A). Data are expressed as percent of Luc-Jc1 HCVcc 
infectivity in the absence of antibody. Means ± SD of four independent experiments 
performed in duplicate are shown. *** P < 0.0001, ** P < 0.001 *, P < 0.01 (t test). 
 
Fig. 5. Kinetics of HCVcc and HCVpp entry demonstrate that CLDN1 mediates 5 
an HCV entry step closely linked to CD81. (A) Schematic drawing of the 
experimental setup. Inhibition of Luc-Jc1 HCVcc entry into Huh7.5.1 cells by heparin 
(250 µg/mL), control monoclonal mouse IgG (5 µg/mL), control rat pre-immune serum 
(1/100), rat anti-CLDN1 serum (1/100), mouse monoclonal anti-CD81 antibody JS-81 
(5 µg/mL) and rat anti-SR-BI serum (1/100) was compared using different protocols 10 
as described in Materials and Methods. Dashed lines indicate the time intervals 
where inhibitors or antibodies were present. All results are expressed as percent Luc-
Jc1 HCVcc infectivity in the absence of inhibitory compound or antibody (CTRL). 
Virus binding to target cells was performed in the presence (protocol I) or absence 
(protocol II) of compounds as described in Materials and Methods. (B) Kinetics of 15 
HCVcc entry into human hepatoma cells by compared protocol I and II. Means ± SD 
of three independent experiments performed in duplicate are shown. (C) Kinetics of 
HCVcc infection into human hepatoma cells in the presence of heparin – an 
attachment inhibitor, anti-CD81 antibody and concanamycin A - an inhibitor of 
endocytosis. Kinetics of HCVcc entry in the presence heparin (●), anti-CD81 (JS-81) 20 
antibody (■), Concanamycin A (♦) (conA; 25nM) or control rat pre-immune serum 
(CTRL) (∆) was determined as described (6, 26, 29, 30). Means of three independent 
experiments performed in triplicate are shown. (D, E) Kinetics of HCVcc entry into 
non-differentiated (D) or DMSO-differentiated (E) Huh7.5.1 cells. The efficiency of 
infection using rat anti-CLDN1 serum (▲), anti-CD81 (JS-81) antibody (■), or control 25 
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rat pre-immune serum (CTRL) (∆) was measured by luciferase assay 48 h later. 
Means of three independent experiments performed in triplicate are shown. (F) 
Kinetics of HCVpp entry in stably transfected 293T/CLDN1+ cells expressing CLDN1 
(as shown in Fig. 1B) using anti-CD81 (JS-81), anti-CLDN1 or control antibodies. 
Means of three independent experiments performed in triplicate are shown.  5 
 
Fig. 6. Dose-dependent inhibition of E2 binding to permissive cell lines by anti-
CLDN1 antibodies. (A) Binding of recombinant E2 glycoprotein to permissive 
Huh7.5.1 cells. Huh7.5.1 cells were pre-incubated with control rat pre-immune serum 
(black lined histograms) or rat anti-CLDN1 antibodies (blue lined histograms) diluted 10 
1/100 for 1 h at RT. Binding of E2 was detected by flow cytometry as described in 
Materials and Methods. Cells incubated in the absence of antibody and E2 (PBS) 
served as negative control (“NC” – light shaded histograms). A representative 
experiment is shown. (B) Binding of recombinant E2 glycoprotein to permissive 
Huh7.5.1 cells. Huh7.5.1 cells were pre-incubated with rat anti-CD81, rat anti-SR-BI 15 
and rat anti-CLDN1 antibodies or control rat pre-immune serum (all diluted 1/100) for 
1 h at RT. Binding of E2 was detected by flow cytometry as described in Materials 
and Methods. Results are expressed as percent E2 binding in the absence of 
antibody (PBS). Means ± SD of four independent experiments performed in duplicate 
are shown. (C) Dose-dependent inhibition of E2 binding to Huh7.5.1 cells by anti-20 
CLDN1. Huh7.5.1 cells were pre-incubated with different dilutions of anti-CLDN1 (■) 
antibodies or control rat pre-immune serum (♦). Results are expressed as percent E2 
binding in the absence of antibody. Means ± SD of four independent experiments 
performed in duplicate are shown. (D) Binding of recombinant E1 glycoprotein to 
permissive Huh7.5.1 cells. Huh7.5.1 cells were pre-incubated with heparin, mouse 25 
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 33 
anti-CD81 (JS-81; 5 µg/mL), control mouse IgG (5 µg/mL), rat anti-CLDN1 (1/100), 
rat pre-immune serum (1/100) for 1 h at RT. Binding of E1 was detected by flow 
cytometry as described (6, 26, 29). Results are expressed as percent E1 binding in 
the absence of antibody (PBS). Means ± SD of two independent experiments 
performed in duplicate are shown. (E) Binding of recombinant E2 glycoprotein to rat 5 
BRL-3A cells stably expressing human SR-BI, CD81 and CLDN1 (24). Cells were 
pre-incubated with mouse anti-CD81 (JS-81, 5 µg/mL), control mouse IgG (5 µg/mL), 
rat anti-SR-BI, rat anti-CLDN1 or rat control serum (all diluted at 1/100) and binding 
of E2 was detected using FITC-conjugated anti-His antibody and flow cytometry as 
described in panel (B). Results are expressed as percent E2 binding in the absence 10 
of antibody (PBS). Means ± SD of two independent experiments performed in 
duplicate are shown. (F) Inhibition of HCVcc binding to permissive Huh7.5.1 cells by 
anti-CLDN1. Huh7.5.1 cells were pre-incubated with heparin (250µg/mL), rat anti-
CLDN1 or control (CTRL) serum (all diluted 1/50) for 1 hour at 37°C prior to 
incubation with HCVcc (Jc1 strain) which had been partially purified from cell culture 15 
supernatants using gradient ultracentrifugation. Following incubation with HCVcc, 
non-bound HCVcc were removed by washing of cells with PBS. Binding of HCVcc 
was then quantified by RT-PCR of cell bound HCV RNA as described (11) which is 
indicated on the y-axis. Means ± SD of five independent experiments performed in 
triplicate are shown. *** P < 0.0001. 20 
 
Fig. 7. Cellular binding of envelope glycoprotein E2 to CHO cells expressing 
CD81 and SR-BI but not CLDN1. (A) Expression of human entry factors in 
transfected CHO cell. CHO cells were transfected with expression plasmids encoding 
human CLDN1, SR-BI or CD81 as described in Materials and Methods. Transfected 25 
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CHO cells were analyzed by flow cytometry using rat control (CTRL), rat anti-CLDN1 
(left panel), rat anti-SR-BI (middle panel) or mouse control IgG and anti-CD81 (JS-
81; right panel) (B) Binding of envelope glycoprotein E2 to CHO cells expressing 
human HCV entry factors. CHO cells were transfected with individual expression 
plasmids encoding for human CLDN1, SR-BI or CD81 as indicated. Cellular E2 5 
binding was analyzed by flow cytometry as described (31). A representative 
experiment performed in duplicate is shown. 
 
Fig. 8. Anti-CLDN1 inhibition of CD81-CLDN1 co-receptor association using 
FRET analysis. 293T cells co-transfected to express AcGFP-CD81 and DsRED-10 
CD81, AcGFP-CLDN1 and DsRED-CD81, or AcGFP-CLDN1 and DsRED-CLDN1 
were seeded onto glass coverslips and treated with pre-immune or anti-CLDN1 sera 
for 1 h. Cells were fixed, imaged by laser scanning confocal microscopy and FRET 
between AcGFP donor and DsRED acceptor proteins measured. % FRET is defined 
as the frequency of pixels demonstrating FRET relative to the total number of pixels 15 
analyzed at the plasma membrane of ten cells. *** P < 0.0001, * P < 0.01. AcGFP-
CLDN1 and DsRED-CD81 at intracellular (black) and plasma membrane (white) 
locations in untreated and anti-CLDN1 treated cells were quantified and the 
percentage of CLDN1 at each location determined. 
Page 78 of 78
Hepatology
Hepatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
